Clinical Trial

ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
Adcendo ApS is conducting a phase 1 study of an investigational drug called ADCE-T02 (previously known as AMT-754), a tissue factor targeted antibody-drug conjugate which may be used in the future as a possible treatment for advanced solid tumors. The main purpose of the study is to determine the Maximum Tolerated Dose (MTD), the recommended dose and the safety and tolerability of ADCE-T02 when given as a single therapy over a range of different dose levels.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-06-30 -> 2027-03-30 2026-07-16
minor Completion pushed: 2026-12-31 -> 2027-06-30 2026-07-16
Trial Details
NCT Number NCT06597721
Lead Sponsor Adcendo ApS
Conditions Advanced Solid Tumor
Enrollment 210 participants
Start Date 2024-11-25
Primary Completion 2027-03-30 (estimated)
Study Completion 2027-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-15